Cadrenal Therapeutics Azioni (NASDAQ: CVKD)

Ultime notizie per Cadrenal Therapeutics (NASDAQ:CVKD) Azioni

Cadrenal Therapeutics

Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics Inc

<p>Barrett Bus Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBSI#NASDAQ">BBSI</a>) reported quarterly earnings of $0.74 per share which beat the analyst consensus estimate of $0.69 by 7.25 percent.  The company reported quarterly sales of $294.278 million which beat the analyst consensus estimate of $287.279 million by 2.44 percent.  This is a 7.66 percent increase over sales of $273.328 million the same period last year.</p>


Earnings

Earnings Beats

News

BBSI

Barrett Bus Servs Q3 2024 GAAP EPS $0.74 Beats $0.69 Estimate, Sales $294.278M Beat $287.279M Estimate

<p><strong>Reaffirming Fiscal Year 2025 Outlook</strong></p>
<p>Kyndryl is reaffirming its outlook for its fiscal year 2025, which runs from April 2024 to March 2025:</p>
<ul>
<li>Adjusted EBITDA margin of at least 16.3%, representing a year-over-year increase of at least 160 basis points.</li>
<li>Adjusted pretax income of at least $460 million, representing a year-over-year increase of at least $295 million.</li>
<li>Constant-currency revenue growth of (2%) to (4%), which now implies fiscal 2025 revenue of $15.2 to $15.5 billion based on recent exchange rates. The Company continues to expect to deliver year-over-year constant-currency revenue growth in the fourth quarter of the fiscal year.</li>
<li>Adjusted free cash flow of approximately $300 million.</li>
</ul>
<p>Forecasted amounts are based on currency exchange rates as of October 2024.</p>


Guidance

Kyndryl Reaffirming FY25 Revenue Growth Outlook Of (2%) To (4%), Which Now Implies Fiscal 2025 Revenue Of $15.2B-$15.5B Vs $15.27B Est.

<p>EnerSys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENS#NYSE">ENS</a>) reported quarterly earnings of $2.05 per share which missed the analyst consensus estimate of $2.07 by 0.97 percent.  The company reported quarterly sales of $883.700 million which missed the analyst consensus estimate of $887.696 million by 0.45 percent.  This is a 1.92 percent decrease over sales of $901.000 million the same period last year.</p>


Earnings Misses

EnerSys Q2 2025 Adj. EPS $2.05 Misses $2.07 Estimate, Sales $883.700M Miss $887.696M Estimate

<p>Coherent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NYSE">COHR</a>) reported quarterly earnings of $0.74 per share which beat the analyst consensus estimate of $0.61 by 21.31 percent. This is a 362.5 percent increase over earnings of $0.16 per share from the same period last year.  The company reported quarterly sales of $1.35 billion which beat the analyst consensus estimate of $1.31 billion by 2.72 percent.  This is a 28.02 percent increase over sales of $1.05 billion the same period last year.</p>


COHR

Coherent Q1 2025 Adj EPS $0.74 Beats $0.61 Estimate, Sales $1.35B Beat $1.31B Estimate

Crane NXT Narrows FY24 Adj. EPS From $4.10-$4.35 To $4.22-$4.30 Vs $4.26 Est; Sees Sales Growth 6%-8%

<p>Tanger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKT#NYSE">SKT</a>) raises FY2024 FFO guidance from $2.05-2.12 to $2.09-2.13 vs $2.09 analyst estimate..</p>


Tanger Raises FY2024 FFO Guidance from $2.05-2.12 to $2.09-2.13 vs $2.09 Est

Guardant Health Raises FY24 Revenue From $690M-$700M To $720M-$725M Vs $695.221M Est.

<p>ModivCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>) reported quarterly earnings of $0.45 per share which missed the analyst consensus estimate of $0.77 by 41.56 percent. This is a 68.75 percent decrease over earnings of $1.44 per share from the same period last year.  The company reported quarterly sales of $702.04 million which missed the analyst consensus estimate of $714.92 million by 1.80 percent.  This is a 2.20 percent increase over sales of $686.92 million the same period last year.</p>


MODV

ModivCare Q3 Adj $0.45 Misses $0.77 Estimate, Sales $702.04M Miss $714.92M Estimate

<p><strong>2024 Financial Guidance</strong></p>
<p>The company now expects 2024 Adjusted EBITDA between $7 billion and $7.150 billion, which is an increase to the midpoint of guidance by $125 million. In addition, the company continues to expect 2024 growth capex between $1.45 billion and $1.75 billion and maintenance capex between $1.1 billion and $1.3 billion, which includes capital of $350 million for emissions reduction and modernization initiatives. For 2025, the company continues to expect Adjusted EBITDA between $7.2 billion and $7.6 billion with growth capex between $1.65 billion and $1.95 billion and maintenance capex between $750 million and $850 million, which includes capital of $100 million for emissions reduction and modernization initiatives. Williams anticipates a leverage ratio midpoint for 2024 of 3.80x and an increase in the dividend by 6.1% on an annualized basis to $1.90 in 2024 from $1.79 in 2023.</p>


Williams Sees FY24 Adj. EBITDA $7B-$7.15B

<p><strong>Outlook</strong></p>
<p>The company is providing the following guidance for fiscal 2025:</p>
<p><figure class="table"><br />
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Fiscal 2025 Guidance</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenues</td>
<td colspan="1" rowspan="1">$1.98 billion</td>
</tr>
<tr>
<td colspan="1" rowspan="1">GAAP Net Income</td>
<td colspan="1" rowspan="1">$624 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">GAAP EPS</td>
<td colspan="1" rowspan="1">$25.05</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Non-GAAP Net Income</td>
<td colspan="1" rowspan="1">$712 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Non-GAAP EPS</td>
<td colspan="1" rowspan="1">$28.58</td>
</tr>
</tbody>
</table>
<p></p></figure>
</p><p>The Non-GAAP financial measures are described in the financial table captioned "Reconciliation of Non-GAAP Guidance."</p>


FICO

Fair Isaac Corp Sees FY25 EPS $28.58 Vs $29.75 Est.; Revenue $1.98B Vs $1.98B Est.

<p><a href="https://www.youtube.com/live/WckEFzGku0Q?si=xYoX2IKIbpXW2PQ7" title="https://www.youtube.com/live/WckEFzGku0Q?si=xYoX2IKIbpXW2PQ7">https://www.youtube.com/live/WckEFzGku0Q?si=xYoX2IKIbpXW2PQ7</a></p>


Politics

General

LIVE: Kamala Harris delivers concession speech - AP

<p>Rapid7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) is looking for Q4 Adj EPS of $0.48-0.51 vs $0.53 analyst estimate. seessales of $211.000 million-213.000 million vs $211.77 million estimate.</p>


Rapid7 Sees Q4 Adj EPS $0.48-0.51 vs $0.53 Est; Sees Sales $211.000M-213.000M vs $211.77M Est

<p>Recursion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.37) by 8.11 percent.  The company reported quarterly sales of $26.082 million which missed the analyst consensus estimate of $29.843 million by 12.60 percent.  This is a 147.62 percent increase over sales of $10.533 million the same period last year.</p>


RXRX

Recursion Pharmaceuticals Q3 2024 GAAP EPS $(0.34) Beats $(0.37) Estimate, Sales $26.082M Miss $29.843M Estimate

<p>TTEC Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTEC#NASDAQ">TTEC</a>) lowers FY2024 Adj EPS guidance from $0.74-0.97 to $0.64-0.83 vs $0.80 analyst estimate. Affirms FY2024 sales outlook from $2.21 billion-2.26 billion to $2.21 billion-2.26 billion vs $2.22 billion estimate.</p>


TTEC

TTEC Holdings Lowers FY2024 Adj EPS Guidance from $0.74-0.97 to $0.64-0.83 vs $0.80 Est; Affirms FY2024 Sales Guidance from $2.21B-2.26B to $2.21B-2.26B vs $2.22B Est

<p>Rapid7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) raises FY2024 Adj EPS guidance from $2.15-2.20 to $2.28-2.31 vs $2.17 analyst estimate. Raises FY2024 sales outlook from $833.00 million-837.00 million to $839.00 million-841.00 million vs $834.13 million estimate.</p>


Rapid7 Raises FY2024 Adj EPS Guidance from $2.15-2.20 to $2.28-2.31 vs $2.17 Est; Raises FY2024 Sales Guidance from $833.00M-837.00M to $839.00M-841.00M vs $834.13M Est

Permian Resources Q3 Oil Sales $1.099B

<p>Bridge Investment Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRDG#NYSE">BRDG</a>) reported quarterly sales of $101.51 million which beat the analyst consensus estimate of $82.90 million by 22.44 percent.  This is a 4.48 percent decrease over sales of $106.27 million the same period last year.</p>


BRDG

Bridge Investment Group Q3 Sales $101.51M Beat $82.90M Estimate

CLOV

Clover Health Sees FY24 Adj. EBITDA Profitability $55M-$65M

<p>Sterling Infrastructure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRL#NASDAQ">STRL</a>) reported quarterly earnings of $1.97 per share which beat the analyst consensus estimate of $1.71 by 15.2 percent. This is a 56.35 percent increase over earnings of $1.26 per share from the same period last year.  The company reported quarterly sales of $593.74 million which missed the analyst consensus estimate of $613.63 million by 3.24 percent.  This is a 5.96 percent increase over sales of $560.35 million the same period last year.</p>


STRL

Sterling Infrastructure Q3 EPS $1.97 Beats $1.71 Estimate, Sales $593.74M Miss $613.63M Estimate

<p>Noodles (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDLS#NASDAQ">NDLS</a>) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.06) by 100 percent.  The company reported quarterly sales of $122.751 million which missed the analyst consensus estimate of $125.853 million by 2.47 percent.  This is a 3.99 percent decrease over sales of $127.854 million the same period last year.</p>


NDLS

Noodles Q3 2024 Adj. EPS $(0.12) Misses $(0.06) Estimate, Sales $122.751M Miss $125.853M Estimate

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Cadrenal Therapeutics, Inc. (CVKD – Research Report) today and set a price targ...

Buy Rating Affirmed for Cadrenal Therapeutics on Strong Clinical and Financial Prospects

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Cadrenal Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/cvkd-stock-quote/"><strong>CVKD</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>Cadrenal Therapeutics reported earnings per share of -10 cents. This was below the analyst estimate for EPS of -7 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/05/cvkd-stock-earnings-cadrenal-therapeutics-for-q1-of-2024/">CVKD Stock Earnings: Cadrenal Therapeutics Misses EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

CVKD Stock Earnings: Cadrenal Therapeutics Misses EPS for Q1 2024

Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Cadrenal Therapeutics, Inc. (CVKD – Research Report), retaining the price ta...

Optimistic Outlook for Cadrenal Therapeutics with Buy Rating Amidst Anticoagulation Market Shifts

The latest announcement is out from Cadrenal Therapeutics, Inc. (CVKD). At the 2024 Annual Meeting of Cadrenal Therapeutics, Inc., stockholders app...

Cadrenal Therapeutics Enhances Incentives and Adjusts Stock Plan

Cadrenal Therapeutics, Inc. (CVKD) has issued an update. Cadrenal Therapeutics has announced a partnership with Abbott to propel its key trial for ...

Cadrenal Therapeutics Partners with Abbott on Cardiac Trial

Abbott to collaborate with Cadrenal on anticoagulant tecarfarin

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Cadrenal Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/cvkd-stock-quote/"><strong>CVKD</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Cadrenal Therapeutics reported earnings per share of -15 cents. This was below the analyst estimate for EPS of -8 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/cvkd-stock-earnings-cadrenal-therapeutics-for-q2-of-2024/">CVKD Stock Earnings: Cadrenal Therapeutics Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

CVKD Stock Earnings: Cadrenal Therapeutics Misses EPS for Q2 2024

Cadrenal Therapeutics, Inc. ( ($CVKD) ) has shared an announcement. Cadrenal Therapeutics, Inc. has refreshed its investor presentation with detail...

Cadrenal Therapeutics Unveils Phase 3 Trials and Market Strategy

Cadrenal Therapeutics, Inc. ( ($CVKD) ) just unveiled an announcement. Cadrenal Therapeutics, a late-stage biopharmaceutical firm, has successfully...

Cadrenal Therapeutics Raises $5.1 Million for Tecarfarin

Cadrenal Therapeutics (CVKD) has raised gross proceeds of approximately $5.1M through its at-the-market facility, selling an aggregate of 391,243 s...

Comments

Cadrenal Therapeutics

Notizie

Ultime notizie per Cadrenal Therapeutics (NASDAQ:CVKD) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO